The Impact of Genome-wide Association Studies On the Pathophysiology and Therapy of Cardiovascular Disease

Overview

Journal EMBO Mol Med

Specialty Molecular Biology

Date 2016 May 19

PMID 27189168

Citations 75

Authors

Thorsten Kessler

Baiba Vilne

Heribert Schunkert

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases are leading causes for death worldwide. Genetic disposition jointly with traditional risk factors precipitates their manifestation. Whereas the implications of a positive family history for individual risk have been known for a long time, only in the past few years have genome-wide association studies (GWAS) shed light on the underlying genetic variations. Here, we review these studies designed to increase our understanding of the pathophysiology of cardiovascular diseases, particularly coronary artery disease and myocardial infarction. We focus on the newly established pathways to exemplify the translation from the identification of risk-related genetic variants to new preventive and therapeutic strategies for cardiovascular disease.

Citing Articles

Clinical and genetic associations of asymmetric apical and septal left ventricular hypertrophy.

Yuan V, Vukadinovic M, Kwan A, Rader F, Li D, Ouyang D Eur Heart J Digit Health. 2024; 5(5):591-600.

PMID: 39318696 PMC: 11417484. DOI: 10.1093/ehjdh/ztae060.

Genome-wide association study of therapeutic response to statin drugs in cardiovascular disease.

Dabiri H, Mortezaei Z Sci Rep. 2024; 14(1):18005.

PMID: 39097628 PMC: 11297937. DOI: 10.1038/s41598-024-68665-4.

Genetic associations of cardiovascular risk genes in European patients with coronary artery spasm.

Tremmel R, Martinez Pereyra V, Broders I, Schaeffeler E, Hoffmann P, Nothen M Clin Res Cardiol. 2024; 113(12):1733-1744.

PMID: 38635033 DOI: 10.1007/s00392-024-02446-x.

The race-based stress reduction intervention (RiSE) study on African American women in NYC and Chicago: Design and methods for complex genomic analysis.

Taylor J, Jones-Patten A, Prescott L, Potts-Thompson S, Joyce C, Tayo B PLoS One. 2024; 19(4):e0295293.

PMID: 38598554 PMC: 11006145. DOI: 10.1371/journal.pone.0295293.

Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure.

Licordari R, Correale M, Bonanno S, Beltrami M, Ciccarelli M, Micari A Biomolecules. 2024; 14(3).

PMID: 38540729 PMC: 10967756. DOI: 10.3390/biom14030309.

References

Zacho J, Tybjaerg-Hansen A, Skov Jensen J, Grande P, Sillesen H, Nordestgaard B . Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008; 359(18):1897-908. DOI: 10.1056/NEJMoa0707402. View

Stasch J, Hobbs A . NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2008; (191):277-308. DOI: 10.1007/978-3-540-68964-5_13. View

. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011; 43(4):339-44. DOI: 10.1038/ng.782. View

Flister M, Hoffman M, Lemke A, Prisco S, Rudemiller N, OMeara C . SH2B3 Is a Genetic Determinant of Cardiac Inflammation and Fibrosis. Circ Cardiovasc Genet. 2015; 8(2):294-304. DOI: 10.1161/CIRCGENETICS.114.000527. View

Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T . Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension. 2011; 59(2):248-55. PMC: 3272453. DOI: 10.1161/HYPERTENSIONAHA.111.181990. View

Nichols M, Townsend N, Scarborough P, Rayner M . Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014; 35(42):2950-9. DOI: 10.1093/eurheartj/ehu299. View

Mayer B, Erdmann J, Schunkert H . Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol. 2006; 96(1):1-7. DOI: 10.1007/s00392-006-0447-y. View

Mega J, Stitziel N, Smith J, Chasman D, Caulfield M, Devlin J . Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015; 385(9984):2264-2271. PMC: 4608367. DOI: 10.1016/S0140-6736(14)61730-X. View

Schunkert H, Samani N . Statin treatment: can genetics sharpen the focus?. Lancet. 2015; 385(9984):2227-9. DOI: 10.1016/S0140-6736(14)61931-0. View

10.

Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T . Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011; 342:d548. PMC: 3039696. DOI: 10.1136/bmj.d548. View

11.

Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes T, Thompson J . Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012; 45(1):25-33. PMC: 3679547. DOI: 10.1038/ng.2480. View

12.

McKeown P, Merlini P, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M . Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009; 41(3):334-41. PMC: 2681011. DOI: 10.1038/ng.327. View

13.

Yang J, Bakshi A, Zhu Z, Hemani G, Vinkhuyzen A, Lee S . Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat Genet. 2015; 47(10):1114-20. PMC: 4589513. DOI: 10.1038/ng.3390. View

14.

Stitziel N, Stirrups K, Masca N, Erdmann J, Ferrario P, Konig I . Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med. 2016; 374(12):1134-44. PMC: 4850838. DOI: 10.1056/NEJMoa1507652. View

15.

Holdt L, Beutner F, Scholz M, Gielen S, Gabel G, Bergert H . ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol. 2010; 30(3):620-7. DOI: 10.1161/ATVBAHA.109.196832. View

16.

Barrett J, Dunham I, Birney E . Using human genetics to make new medicines. Nat Rev Genet. 2015; 16(10):561-2. DOI: 10.1038/nrg3998. View

17.

Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton J, Tsai D . Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2011; 340(2):228-36. DOI: 10.1124/jpet.111.187419. View

18.

Braenne I, Civelek M, Vilne B, Di Narzo A, Johnson A, Zhao Y . Prediction of Causal Candidate Genes in Coronary Artery Disease Loci. Arterioscler Thromb Vasc Biol. 2015; 35(10):2207-17. PMC: 4583353. DOI: 10.1161/ATVBAHA.115.306108. View

19.

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

20.

Barrett J, Clayton D, Concannon P, Akolkar B, Cooper J, Erlich H . Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009; 41(6):703-7. PMC: 2889014. DOI: 10.1038/ng.381. View